Deal could put FDA reps in China

Share this article:

A deal between the US and China could mean more FDA inspection of manufacturing plants. Regulatory Focus reports that the countries struck a deal Dec. 5 that officials say will mean “a substantial increase in the number of US food and drug inspectors” on site.

The news could mean a new rash of Warning Letters to read up on: RF notes that on-site inspections in India, for example, netted six Warning Letters in 2012, and inspectors also put a dent in businesses including Wockhardt and Fresenius Kabi, after finding problems with their facilities.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies